Latest FDA Guidance Allows Distribution of SARS-CoV-2 Serology Tests for Diagnostic Use

Yesterday, March 16, the FDA updated its “Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency” document. The document can be downloaded by clicking here.

As a result, BioMedomics will be able to distribute our COVID-19 IgM-IgG Antibody Rapid Test to any licensed healthcare practitioner in the United States for diagnostic use starting on March 17, 2020.

Click here for more information about our COVID-19 Rapid Test.


Share on facebook
Share on twitter
Share on linkedin


Comments are closed for this article!